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Respiratory	Microbiota	and	Lower	
Respiratory	Tract	Disease	
Introduction:	The	respiratory	airways	harbor	a	complex	succession	of	ecological	niches	
with	 distinct	 but	 related	 bacterial	 communities.	 Particular	 challenges	 of	 respiratory	
microbiome	research	have	 led	 to	 limited	scientific	output	compared	 to	other	human	
microbiomes.		
	
Areas	 covered:	 In	 this	 review,	we	 summarize	 the	 current	 state	 of	 knowledge	 of	 the	
bacterial	respiratory	microbiome,	with	a	particular	focus	on	associations	between	the	
respiratory	microbiome	and	lower	respiratory	tract	conditions.	
	
Expert	commentary:	There	is	growing	evidence	that	the	respiratory	microbiome	is	
associated	with	lower	respiratory	infectious	diseases	and	related	conditions.	Most	
respiratory	microbiome	reports	are	metataxonomic	cross-sectional	or	case-control	
studies	with	relatively	small	sample	sizes.	Large,	prospective	projects	with	
metatranscriptomics	or	metabolomics	approach	are	needed	to	unravel	the	effect	of	
the	respiratory	microbiome	on	health-related	conditions.	Moreover,	standardization	in	
sampling,	library	preparation,	sequencing	techniques	and	data	analysis	should	be	
encouraged.	 	
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1.	Introduction	
In	the	past	decade,	we	have	witnessed	an	exponential	increase	in	human	microbiome	
related	 research,	 from	around	300	publications	 in	2006	 to	almost	8000	 in	2016.	The	
development	of	novel	culture-independent	techniques	of	microbial	identification,	and	
decreasing	costs	of	sequencing	platforms	have	enabled	research	in	this	exciting	field,	
producing	relevant	findings	that	have	changed	and	broaden	our	perspective	on	host-
microbe	and	microbe-microbe	 interactions.	 Important	paradigm	shifts	have	occurred	
during	 this	 process,	 including	 the	 recognition	 of	 the	 diversity	 and	 abundance	 of	 the	
microbial	 community	 in	 healthy	 individuals,	 the	 discovery	 of	 viable	 communities	 in	
body	 sites	previously	 considered	 sterile,	 and	more	 importantly,	 the	establishment	of	
associations	between	human	microbiome	and	health.	
	
Most	of	the	research	conducted	so	far	has	focused	on	the	gut	microbiota,	the	body	site	
containing	the	richest	and	most	complex	bacterial	communities.	In	2008,	the	National	
Institutes	 of	 Health	 and	 the	 European	 Commission	 launched	 two	multicentric	mega	
projects:	the	Human	Microbiome	Project,	where	samples	from	up	to	18	body	sites	of	
healthy	individuals	were	collected,	and	MetaHIT,	focused	on	the	metagenomics	of	the	
intestinal	 tract.1,2	 The	 respiratory	 tract	was	 left	 apart,	 partly	because	of	problems	 in	
collecting	 lower	 respiratory	 tract	 samples,	 but	 also	 because	 lungs	 have	 traditionally	
been	 considered	 sterile.	 Recent	 studies	 have	 shown	 that	 the	 lower	 respiratory	 tract	
harbours	 a	 diverse	 bacterial	 community	 both	 in	 healthy	 and	 diseased	 individuals,	
which	has	boosted	respiratory	microbiota	research	that	is	currently	growing	rapidly.3	
	
Acute	 lower	 respiratory	 infections,	 such	 as	pneumonia	 and	bronchiolitis	 are	 a	major	
public	 health	 concern	 globally,	 accounting	 for	 a	 large	 burden	 of	 mortality	 and	
hospitalization	 in	 children.4-6	 Chronic	 conditions,	 such	 as	 asthma	 and	 chronic	
obstructive	pulmonary	disease	(COPD),	show	a	high	and	growing	prevalence	globally,	
with	respiratory	infections	being	involved	in	pathogenesis	and	course	of	the	disease.7-
10	 Respiratory	 microbiota	 research	 may	 reveal	 new	 perspectives	 regarding	 host-
microbe	 interactions	 leading	 to	 a	 particular	 local	 environment	 contributing	 to	 the	
pathogenesis	of	lung	and	airways	conditions.	These	deeper	insights	could	later	be	the	
basis	 for	 novel	 preventive	 and	 therapeutic	 measures	 to	 complement	 or	 adapt	 the	
currently	available	arsenal	against	respiratory	infectious	diseases.	
	
Besides	 an	 initial	 overview	of	 respiratory	microbiota	 composition	and	dynamics,	 this	
review	 aims	 to	 summarize	 published	 evidence	 of	 associations	 between	 respiratory	
microbiota	and	different	respiratory	conditions.	
2.	Terminology	and	methods	
Most	microbiota	 studies	 rely	on	 sequencing	variable	 regions	of	 the	highly	 conserved	
gene	 encoding	 the	 16	 small	 subunit	 of	 ribosomal	 RNA	 (16SrRNA).	 This	 gene	 is	
universally	present	 in	bacteria	and	absent	 in	mammals,	and	contains	9	hypervariable	
regions	(V1	to	V9)	allowing	the	identification	of	different	bacteria	through	taxonomic	
assignment	of	the	obtained	sequences	using	reference	genomes.11	Depending	on	the	
sequences	and	 the	available	databases,	 identification	can	be	achieved	 to	 the	species	
level	 but	 usually	 results	 in	 a	 mix	 of	 species,	 genera,	 phylum,	 and	 taxa	 levels.	 To	
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describe	 the	 output	 of	 microbial	 identification,	 the	 generic	 term	 organizational	
taxonomic	unit	(OTU)	is	usually	adopted.	This	process	is	defined	as	metataxonomics	as	
it	 describes	 the	 taxonomic	 composition	 of	 the	 entire	 bacterial	 community.	 This	 has	
two	 important	 implications:	 first,	 viruses	 and	 fungus	 (which	 lack	 the	 16S	 rRNA	 gene	
although	 similar	 profiling	 methods	 based	 on	 the	 18S	 rRNA	 gene	 are	 available	 for	
fungus)	are	not	identified	albeit	being	an	integral	part	of	the	microbiota,	and	second,	
this	process	does	not	provide	information	about	the	function	of	the	microbiota,	which	
can	 only	 be	 gained	 through	 metagenomics	 or	 other	 omics	 platforms,	 such	 as	
metatranscriptomics	 and	 metabolomics.	 Key	 terms	 used	 in	 microbiota	 research	 are	
defined	in	Table	1.	
3.	Ecological	niches	and	dynamics	of	the	respiratory	microbiota	
3.1.	Microbiota	acquisition	of	the	upper	respiratory	tract	
From	a	bacterial	ecological	perspective,	the	human	respiratory	tract	 is	a	sequence	of	
niches	from	the	anterior	nares	and	mouth	to	the	lungs	harbouring	distinct	but	related	
bacterial	 communities.	 There	 is	 recent	 evidence	 of	 foetal	 microbial	 colonization	
starting	 in	 utero,12,13	 with	 intensification	 of	 the	 process	 immediately	 after	 birth.	
Maternal	 bacteria	 rapidly	 colonize	 cutaneous	 and	mucosal	 surfaces	 of	 the	 newborn,	
with	 predominance	 of	 vaginal	 and	 intestinal	 maternal	 microbiota	 in	 case	 of	 vaginal	
delivery,	 and	 of	 skin	 microbiota	 in	 births	 resulting	 from	 caesarean	 sections.14	 The	
anterior	 nares	 display	 a	 relatively	 simple	 microbiota	 with	 few	 differences	 between	
children	and	adults.	Corynebacterium,	Propionibacterium	 and	Staphylococcus	 are	 the	
initial	colonizers	of	the	anterior	nares	and	maintain	their	predominance	until	adult	life	
where	Moraxella	has	also	been	described	together	with	the	three	genera	above.15	 In	
contrast,	nasopharyngeal	microbiota	 is	a	more	complex	and	dynamic	ecosystem	with	
important	 changes	 over	 time.	 Differentiation	 into	 site-specific	 microbiota	 is	 a	
multifactorial	 process	 that	 starts	 after	 initial	 colonization	 and	 can	 last	 to	 up	 to	 two	
years	of	age	depending	on	body	sites,	with	the	upper	respiratory	tract	microbiota	of	
children	 18	months	 of	 age	 still	 showing	 distinct	 characteristics	 compared	 to	 that	 of	
adults.16,17	 Initially,	Corynebacterium	and	Staphylococcus	dispersing	from	the	anterior	
nares	 colonize	 the	nasopharynx	 that	 subsequently	gains	Dolosigranulum	 (particularly	
in	 breastfed	 infants),	 Alloiococcus	 and	Moraxella.18-20	 In	 adults,	 the	 inter-individual	
diversity	 in	 nasopharyngeal	 microbiota	 is	 reduced,	 Corynebacterium	 is	 usually	 the	
dominant	 genus,	 and	 Moraxella	 and	 Dolosigranulum	 are	 much	 less	 frequently	
represented.21-23	The	oral	cavity	shows	the	same	initial	colonization	strongly	influenced	
by	delivery	mode	as	the	other	body	sites,	but	rapidly	gains	a	higher	richness	due	to	a	
high	 exposure	 to	 the	 external	 environment,	 the	 presence	 of	 saliva	 characterized	 by	
abundance	of	Prevotella,	Neisseria,	and	Haemophilus,	and	later	on,	by	the	eruption	of	
teeth	 entailing	 an	 increase	 in	Bacteroidetes,	 particularly	Veillonella	 and	Prevotella.24	
Despite	 being	 highly	 exposed	 to	 foodborne	 and	 environmental	 bacteria,	 the	 oral	
microbiota	 is	 remarkably	 stable	 over	 time.25	 The	 oropharynx	 is	 an	 anatomical	
crossroad	 between	 the	 upper	 respiratory	 structures,	 and	 the	 lower	 airways	 and	
gastrointestinal	 tract	 resulting	 in	 a	 rich	 and	 highly	 variable	 bacterial	 ecosystem.	
Common	genera	described	 in	healthy	 adults	 include	Streptococcus	 (both	 commensal	
and	 potentially	 pathogenic	 such	 as	 S.	 pneumoniae	 and	 S.	 pyogenes),	 Haemophilus,	
Neisseria,	Prevotella,	Veillonella	 and	Leptotrichia.26,27	 Similar	 to	what	happens	 in	 the	
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gut	 mucosa	 and	 skin	 surface,	 the	 early	 colonization	 of	 upper	 airways	 plays	 an	
important	role	 in	 immune	maturation	and	immune	response	modulation	of	the	host,	
as	suggested	in	studies	where	germ-free	mice	showed	exaggerated	airway	eosinophilia	
and	 accumulation	 of	 invariant	 natural	 killer	 T-cells	 that	 did	 not	 occur	 in	 colonized	
mice.28-31	 Initially,	 the	 neonate	 immune	 system	 is	 skewed	 towards	 a	 regulatory	
response	allowing	microbiota	colonization	without	inflammatory	response.	The	risk	of	
having	an	immature	immune	system	at	birth	is	rapidly	compensated	by	the	beneficial	
effect	of	having	a	 stable	commensal	microbiota	conferring	 resistance	 to	colonization	
by	 pathogenic	 bacteria.	 The	 contact	 between	 resident	 microbiota	 and	 the	 infant	
immune	system	is	limited	by	physical	barriers	such	as	mucus	layers,	and	modulated	by	
metabolites,	microbes,	 and	 IgA	 contained	 in	maternal	milk,	 leading	 to	 immunogenic	
tolerance	and	the	establishment	of	a	stable	host-microbiota	relationship.32	Despite	the	
virtually	 absent	 inflammatory	 response	 against	 stable	 microbiota,	 the	 constant	
exposure	to	 limited	amounts	of	bacterial	antigens	contributes	to	the	development	of	
the	immune	system.	
3.2.	The	lower	respiratory	tract	microbiota	
The	 healthy	 lung	 sterility	 paradigm	 has	 repeatedly	 been	 challenged	 since	 the	
introduction	 of	 culture-independent	 techniques.	 However,	 this	 does	 not	 imply	 the	
existence	of	stable	colonization	of	the	lungs	and	it	is	commonly	accepted	that	bacterial	
detection	 in	 lower	 airways	 samples	 is	 likely	 due	 to	 equilibrium	 between	 constant	
inoculation	 of	 upper	 respiratory	 microbiota	 by	 micro-aspiration,	 and	 clearance	 by	
respiratory	 endothelium	 cilia	 and	 cough.33-35	 Venkataraman	 et	 al.	 showed	microbial	
composition	of	the	healthy	lung	in	adults	was	consistent	with	the	neutral	community	
model,	 i.e.,	 bacterial	 dispersal	 from	 upper	 respiratory	 niches,	 particularly	 the	 oral	
cavity,	 explained	 lung	microbial	 communities.36	 Interestingly,	 viable	bacteria	 account	
for	61%	of	the	recovered	OTUs.	In	diseased	lungs,	however,	selection	seemed	to	shape	
bacterial	 communities,	 suggesting	 stable	 colonization.	 In	 healthy	 lungs,	 bronchioles	
and	 alveoli	 are	 covered	 with	 surfactant	 and	 its	 low	 content	 in	 nutrients	 impair	
bacterial	 growth.37	 In	 case	 of	 infection,	 the	 high	 protein	 content	 exudate	 resulting	
from	inflammatory	response	serves	as	substrate	for	bacterial	overgrowth.	Studies	have	
shown	 the	 composition	of	 the	microbiome	of	 the	 lower	airways	 in	healthy	adults	 to	
correlate	with	that	of	the	upper	airways,	particularly	the	oropharynx,	but	to	be	much	
lower	 in	 abundance	 (from	105	bacteria	per	milliliter	of	nasopharyngeal	 fluid	 to	101	 -
102/mL	of	BAL	 fluid).38-41	Similar	 results	have	been	obtained	 in	children,	except	 for	a	
greater	 contribution	 of	 nasopharyngeal	 microbiota	 in	 lower	 airways’	 microbiota	
composition.42	 Segal	 et	 al.	 partially	 challenge	 these	 findings.	 In	 two	 cross-sectional	
studies	 with	 healthy	 adults,	 they	 determined	 two	 distinct	 pneumotypes	 based	 on	
bronchoalveolar	 lavage	 (BAL)	 samples,	 one	 enriched	 with	 bacteria	 from	 the	 upper	
respiratory	 tract	 and	 present	 in	 around	 45%	of	 participants,	 and	 the	 other	 enriched	
with	 background	 bacteria.43,44	 The	 first	 pneumotype	 was	 associated	 with	 increased	
pulmonary	 inflammation	measured	by	 exhaled	 nitric	 oxide	 and	BAL	 cells	 count.	 This	
subclinical	inflammation	characterized	by	increased	Th17	response	might	be	beneficial	
for	the	host,	as	suggested	by	animal	models	of	Staphylococcus	aureus	pneumonia.45		
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4.	Respiratory	microbiota	and	lower	respiratory	conditions	
We	 systematically	 reviewed	 the	 literature	 to	 retrieve	 original	 papers	 describing	
associations	 between	 respiratory	 microbiota	 and	 lower	 respiratory	 tract	 infections	
(Box	 1).	We	excluded	HIV	 infected	patients,	 as	 it	was	 object	 of	 a	 recently	 published	
review.3	A	total	of	25	articles	were	retained	for	this	section,	13	in	adults,46-58	and	11	in	
children.19,59-69	 An	 overview	 of	 the	 studies	 characteristics	 is	 summarized	 in	 tables	 2	
(adults)	and	3	(children).	
4.1.	Pneumonia	and	ventilator-associated	pneumonia	
Despite	 differences	 in	 study	 populations	 and	 samples,	 similar	 patterns	 have	 been	
observed	 in	 patients	 with	 pneumonia.	 In	 general,	 such	 patients	 display	 a	 more	
abundant	 microbiota	 with	 less	 diversity,	 richness	 and	 evenness,	 and	 these	
disturbances	 can	 be	 observed	 in	 upper	 and	 lower	 respiratory	 tract	 microbiota,	
particularly	 in	 adults.	 The	 microbiota	 of	 patients	 with	 pneumonia	 seems	 to	 be	
dominated	 by	 one	 taxon,	 showing	 a	 higher	 relative	 abundance	 of	 Streptococcus,	
Haemophilus	 or	Moraxella.	 Dominance	 by	 Streptococcus	 pneumoniae,	 Burkholderia,	
Bacillales,	 and	 to	 a	 lesser	 extent,	Pseudomonadales	 was	 particularly	 correlated	with	
decreased	 diversity.58,68	 In	 studies	 with	 repeated	 sampling,	 the	 dominance	 of	 one	
taxon	was	maintained	over	time,	and	its	relative	abundance	increased	throughout	the	
pneumonia	 episode,	 particularly	 if	 the	 patient	 was	 intubated.51	 Intubation	 was	
consistently	a	 risk	 factor	 for	bacterial	disturbance	 in	 the	 lower	 respiratory	 tract	 (low	
diversity	and	evenness)	supporting	the	hypothesis	of	a	lung	microbiota	resulting	from	
the	 equilibrium	 between	 microaspirations	 from	 the	 upper	 respiratory	 tract	 and	
clearance	mechanisms.34,51,58,63	Antibiotic	administration	seemed	to	have	less	effect	on	
bacterial	diversity	than	intubation,58	and	this	effect	was	transitory,	with	recovery	of	a	
similar	 oropharyngeal	microbiota	 a	 few	days	 after	 antibiotic	 treatment	 compared	 to	
the	microbiota	 before	 antibiotic	 administration.52	 However,	most	 of	 the	 studies	 did	
not	assess	this	effect,	probably	due	to	difficulties	 in	assuming	bacterial	viability	 from	
DNA	based	measures.70,71	In	an	early	study	assessing	the	effect	of	antibiotics	in	seven	
intubated	 adults	 colonized	 by	 Pseudomonas	 aeruginosa,	 Shannon’s	 diversity	 index	
significantly	 fell	 from	 1.48	 to	 0.59	 after	 a	 few	 days	 of	 antibiotic	 treatment,	 with	 P.	
aeruginosa	coming	to	dominate	the	microbiome	in	most	patients	despite	susceptibility	
in	 vitro	 to	 the	 administered	 antibiotics.72	No	 taxon	was	 consistently	 associated	with	
health,	 although	 some	 associations	 were	 found.	 Prevotella	 dominant	 oropharyngeal	
microbiota	was	more	 frequent	 in	healthy	 adults	 than	 in	 adults	with	pneumonia,	 but	
more	frequent	in	older	children	with	severe	pneumonia	than	in	non-severe	pneumonia	
cases.46,66	 Veillonella	 and	 Dolosigranulum	 were	 frequently	 sequenced	 in	 healthy	
individuals	or	patients	with	less	severe	pneumonia	in	upper	respiratory	tract	samples,	
the	latter	particularly	in	young	children.46,66,67,73	Interestingly,	despite	Moraxella	being	
associated	 with	 pneumonia,	Moraxella	 lacunata	 was	 significantly	 more	 frequent	 in	
pediatric	viral	vs.	non-viral	pneumonia,	and	more	frequent	in	controls	than	in	all-cause	
pneumonia,	 highlighting	 the	 necessary	 caution	 in	 establishing	 associations	 based	 on	
phylum	or	genera-level	taxonomics.67	
	
Interesting	 inconsistencies	 merit	 further	 examination.	 In	 a	 study	 in	 adults	 with	
community-acquired	 pneumonia	 and	 healthy	 controls,	 oropharyngeal	 microbiota	
dominated	by	Lactobacillales	 (predominantly	Streptococcus	spp.)	was	associated	with	
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pneumonia.46	 This	 result	 was	 partly	 consistent	 with	 a	 pediatric	 study	 assessing	 the	
association	 between	 upper	 and	 lower	 respiratory	 tract	 microbiota	 and	 pneumonia	
severity.66	 Presence	 of	 Lactobacillales	 was	 associated	 with	 longer	 hospital	 stay	 in	
children	older	than	five	years	of	age,	but	with	a	 less	severe	pneumonia	 in	under-five	
children	 underscoring	 the	 importance	 of	 age-related	 host-microbe	 interactions	 and	
immune	system	dynamics.	Two	studies	did	not	 support	 the	association	between	 low	
microbiota	diversity	and	disease.	Toma	et	al.	compared	the	microbiota	of	endotracheal	
aspirates	 from	 intubated	 adults	 with	 possible	 ventilator-associated	 pneumonia	 and	
found	no	differences	in	diversity	when	comparing	low	and	high-risk	groups	as	per	the	
Clinical	 Pneumonia	 Infection	 Score	 (CPIS).56	 However,	 there	 were	 no	 significant	
differences	between	groups	in	most	of	the	items	included	in	the	CPIS,	and	the	authors	
did	 not	 report	 clinical	 outcomes	 at	 the	 end	 of	 the	 admission,	 raising	 concerns	 of	
misclassification.	Wang	et	al.	compared	the	microbiota	of	bronchoalveolar	lavage	fluid	
in	 children	 with	 pneumococcal	 and	 Mycoplasma	 pneumonia	 with	 controls,	 and	
reported	that	controls	had	the	lowest	microbial	diversity.68	This	could	be	evidence	of	
age-dependent	differences	in	health	and	disease,	although	caution	is	warranted	at	this	
stage	of	microbiome	research.	Noteworthy,	controls	 (n=11)	were	younger	than	cases	
and	 had	 tracheomalacia,	 which	may	 play	 a	 role	 in	 impaired	 clearance	 of	 the	 lower	
respiratory	tract	in	individuals	from	an	age	group	with	a	respiratory	microbiota	yet	to	
be	fully	developed.		
4.2.	Bronchiolitis	and	asthma	
Recurrent	 wheezing	 and	 asthma	 in	 childhood	 are	 strongly	 associated	 with	 having	
suffered	a	bronchiolitis	episode	during	the	first	year	of	 life,	particularly	when	caused	
by	 respiratory	 syncytial	 virus	 (RSV)	 or	 human	 rhinovirus	 (HRV).	 We	 retrieved	 six	
original	papers	assessing	 the	 respiratory	microbiota	 in	 infants	with	bronchiolitis,	 and	
one	 in	 children	 and	 adolescents	 with	 asthma,	 with	 all	 of	 them	 using	 upper	 airways	
samples.19,59-62,64,69	 The	 article	 on	 asthma	 was	 included	 because	 it	 focused	 on	 the	
infectious	 component	 of	 recurrent	 wheezing	 pathophysiology.	 Despite	 a	 smaller	
variability	 in	 study	 population	 and	 in	 sampling	 sites	 than	 in	 the	 aforementioned	
pneumonia	 studies,	 findings	 in	 this	 condition	 are	 discordant.	 While	 there	 is	 some	
degree	 of	 consensus	 in	 describing	 a	 decreased	 evenness	 in	 both	 asthma	 and	
bronchiolitis,	discrepancies	arise	on	which	phylum	or	genus	dominates	the	microbiota.	
Most	 studies	 associate	 Proteobacteria	 (phylum)	 and	 Moraxella	 or	 Haemophilus	
(genera)	dominant	taxa	 in	upper	respiratory	microbiota	with	asthma,	bronchiolitis	or	
severity	of	bronchiolitis.19,59,62,69	On	the	other	hand,	in	a	case-control	study	with	infants	
with	bronchiolitis	and	healthy	controls,	Hasegawa	et	al.	described	four	distinct	profiles	
of	upper	respiratory	microbiota,	each	of	them	dominated	by	a	taxon,	with	infants	with	
the	Moraxella	dominant	profile	having	the	lowest	risk	of	having	bronchiolitis,	and	the	
Staphylococcus	 dominant	 profile	 presenting	 an	 odds	 ratio	 of	 5	 for	 bronchiolitis.60	
Interestingly,	 Dolosigranulum	 dominant	 profile	 also	 presented	 a	 very	 low	 risk	 of	
bronchiolitis,	consistent	with	the	findings	we	described	above	in	the	section	dedicated	
to	pneumonia.	In	another	large	case-series	published	by	the	same	author	assessing	the	
association	 of	 microbiota	 and	 bronchiolitis	 severity,	 Moraxella	 dominant	 profiles	
presented	 again	 the	 lowest	 risk	 of	 a	 negative	outcome	 (defined	 as	 admission	 to	 the	
intensive	care	unit).61	 In	this	series,	the	profile	with	highest	risk	of	negative	outcome	
was	the	Haemophilus	dominant	one,	consistent	with	most	of	the	studies.	Seasonal	or	
geographical	 effects	 do	 not	 explain	 these	 discrepancies	 as	most	 of	 the	 studies	were	
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conducted	 in	 the	US	 in	winter	and	merit	 further	 investigation.	Four	 studies	 reported	
data	on	viral	etiology	and	suggested	virus-bacteria	interactions	in	the	pathogenesis	of	
bronchiolitis	and	future	recurrent	wheezing,	particularly	between	Proteobacteria	and	
RSV.19,62,69	The	chronology	of	 the	 interaction,	 i.e.,	whether	a	viral	 infection	alters	 the	
epithelium	 environment	 allowing	 for	 a	 greater	 bacterial	 adherence	 or	 a	 colonizing	
bacteria	predisposes	to	viral	infection,	is	still	unclear,	although	there	is	some	evidence	
supporting	 the	 former	 at	 least	 in	 case	 of	 human	 rhinovirus	 infection	 (hRV).	 In	 a	
prospective	 study	 with	 weekly	 nasal	 samples	 collected	 from	 children	 aged	 four	 to	
twelve	 years	 old,	 detection	 of	 hRV	 increased	 the	 risk	 of	 concurrent	 or	 subsequent	
detection	 of	 pathogenic	 bacteria	 (either	 S.	 pneumoniae,	 H.	 influenzae	 or	 M.	
catharralis),	whereas	the	opposite	was	not	observed.74	In	a	randomized	controlled	trial	
in	infants	with	RSV-bronchiolitis	admitted	to	hospital,	Zhou	et	al.	assessed	the	effect	of	
a	14-days	course	of	azithromycin	(AZM)	on	future	recurrent	wheezing,	reporting	a	50%	
reduction	over	 the	 following	 12	months.69	Nasal	 lavages	 samples	were	 taken	before	
and	after	the	treatment	showing	a	significantly	higher	reduction	in	Moraxella	relative	
abundance	 in	 the	 treatment	 group.	 Cautiously,	 the	 authors	 recognized	 difficulties	
unfolding	 the	direct	 anti-inflammatory	effect	of	AZM	on	 respiratory	 airways	 and	 the	
indirect	effect	through	Moraxella	depletion	on	the	recurrent	wheezing	reduction.	On	
the	 other	 hand,	 Mansbach	 et	 al.	 found	 that	 in	 infants	 hospitalized	 with	 severe	
bronchiolitis,	 RSV	 mono-infection	 was	 associated	 with	 high	 relative	 abundance	 of	
Firmicutes	 (Streptococcus)	 and	 low	 abundance	 of	 Proteobacteria	 (Moraxella	 and	
Haemophilus),	with	an	inverse	association	in	HRV	mono-infection.64	To	note,	this	case-
series	is	the	same	as	the	one	described	by	Hasegawa	et	al.		
4.3.	Bronchiolitis	obliterans	syndrome	(BOS)	
Lung	 transplant	 recipients	 face	 a	 higher	 risk	 of	 acute	 and	 chronic	 rejection	 of	 the	
allograft	than	other	solid	organ	recipients,	with	BOS	being	the	leading	cause	of	death	
after	 the	 first	 year.75	 Although	 epidemiologically	 less	 relevant	 than	 pneumonia	 and	
asthma,	 the	 dramatic	 outcome	 of	 BOS	 and	 the	 host-microbe	 interactions	 involved	
merit	 a	 closer	 attention.	 Traditionally,	 proper	 immunosuppression	 and	 aggressive	
antibiotic	treatment,	particularly	against	Pseudomonas	aeruginosa	have	been	the	main	
pillars	 in	 BOS	 prevention	 and	 management.76	 Case-control	 studies	 using	 culture-
independent	techniques	are	providing	notable	insight	that	may	change	our	perception	
of	 BOS	pathogenesis.47,57	 Lung	 transplant	 patients	 harbor	 a	more	 abundant	 and	 less	
diverse	 lower	 airways	 microbiota	 than	 non-transplant	 patients.	 Two	 main	
pneumotypes	have	been	described	according	to	genera	dominance,	one	dominated	by	
Pseudomonas	 and	 the	 other	 dominated	 by	 Veillonella,	 Prevotella	 or	 Streptococcus.	
These	 pneumotypes	 seem	 to	 be	 mutually	 exclusive,	 and	 although	 Pseudomonas	
abundance	is	associated	with	low	diversity,	which	is	in	turn	associated	with	higher	BAL	
neutrophilia	and	bacterial	DNA	burden,	assigning	a	healthy	or	unhealthy	label	to	these	
pneumotypes	 is	not	straightforward.	Dickson	et	al.	assessed	the	association	between	
BAL	 microbiota	 and	 BOS	 in	 33	 adults	 with	 lung	 transplant,	 and	 identified	 an	
uncommon	Pseudomonas	species,	Pseudomonas	fluorescens.47	Almost	all	the	patients	
with	P.	aeruginosa	had	symptoms	associated	with	BOS,	whereas	all	the	patients	with	
P.	 fluorescens	 were	 symptom-free.	 A	 case-control	 study	 with	 57	 lung	 transplant	
recipients	and	8	controls	conducted	by	Willner	et	al.	yielded	results	requiring	a	close	
attention.57	 Half	 of	 the	 lung	 transplant	 recipients	 had	 cystic	 fibrosis	 (CF),	with	 all	 of	
them	 being	 colonized	 by	 P.	 aeruginosa	 prior	 to	 transplantation.	 In	 this	 group,	
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recolonization	by	P.	aeruginosa,	usually	from	upper	airways	reservoirs,	was	negatively	
associated	with	BOS	(OR	0.25;	95%	confidence	 interval	0.09-0.65),	whereas	presence	
of	 newly	 acquired	P.	 aeruginosa	was	 associated	with	 developing	 BOS	 in	 the	 non-CF	
subgroup.	These	results	might	partly	be	explained	by	the	phenotypic	changes	suffered	
by	 P.	 aeruginosa,	 transitioning	 from	 an	 aggressive	 form	 with	 high	 expression	 of	
virulence	factors	when	acquired	de	novo	to	a	more	passive	phenotype	after	long-term	
colonization	showing	less	invasiveness	and	thus	eliciting	immunogenic	response.77	The	
authors	 conclude	 the	 reestablishment	 of	 pre-transplant	 populations	 in	 the	 allograft	
appear	 to	 protect	 against	 BOS,	 which	 supports	 the	 hypothesis	 of	 immunogenic	
tolerance	in	airways	inflammation.	
4.4.	Others	
This	section	includes	a	miscellanea	of	lower	respiratory	tract	conditions	in	adults,	from	
non-transplanted	cystic	 fibrosis	 and	non-CF	bronchiectasis	 to	 interstitial	 lung	disease	
and	 idiopathic	 pulmonary	 fibrosis,	 all	 of	 them	 directly	 or	 indirectly	 associated	 with	
infection.48,49,53,54	 Three	 studies	 assessed	 the	 association	 between	 respiratory	
microbiota	 and	 lung	 function,	 measured	 by	 spirometry,	 and	 found	 a	 correlation	
between	microbiota	diversity	and	forced	expiratory	volume	in	1	second	(FEV1).48,53,54	
In	one	of	these	studies,	however,	the	lung	function	deterioration	seemed	to	be	driven	
more	by	bacterial	abundance	than	microbiota	diversity	or	composition.53	Patients	with	
idiopathic	pulmonary	fibrosis	had	slightly	lower	diversity	than	controls	(Shannon	index	
3.8	 vs.	 4.1)	 and	 similar	 microbiota	 composition	 with	 Streptococcus,	 Prevotella	 and	
Veillonella	 accounting	 for	 50%	 of	 reads	 in	 both	 groups,	 but	 significantly	 higher	
abundance	 than	 controls.	 These	 findings	were	 also	 reported	 in	 a	 sub-group	 analysis	
comparing	progressors	and	non-progressors	among	cases.	To	note,	controls	 included	
patients	with	moderate	COPD,	which	 is	 associated	with	 lower	microbiota	diversity.78	
On	the	other	hand,	Garzoni	et	al.	compared	the	microbiota	composition	and	diversity	
in	 upper	 and	 lower	 respiratory	 tract	 samples	 from	 24	 patients	 with	 interstitial	 lung	
disease	 or	 Pneumocystis	 jirovecii	 pneumonia	 and	 9	 healthy	 controls,	 and	 found	 no	
differences	 in	 richness,	 diversity	 and	 presence	 of	 commensals	 such	 as	 Prevotella	 or	
Acidaminococcaceae	 suggesting	 no	 effect	 of	 respiratory	 microbiota	 in	 the	 disease	
process.49	 The	 small	 sample	 size	 and	 the	 variety	 of	 diagnoses	 in	 the	 disease	 group	
could	arise	concerns	about	 the	 internal	validity	of	 this	 study,	but	 if	 confirmed,	 these	
negative	 results	 could	 help	 researchers	 in	 narrowing	 the	 pathophysiology	 of	 host-
microbe	interactions	in	lung	disease.	
5.	Conclusion	
Despite	the	variability	of	study	populations,	samples	and	methods	used	in	the	original	
papers	 included	 in	 this	 review,	 patterns	 in	 the	 effect	 of	 respiratory	 microbiota	 on	
lower	 respiratory	 tract	 infections	 and	 infection-related	 conditions	 start	 to	 arise,	
although	 a	 clear	 healthy	 respiratory	 microbiota	 is	 still	 to	 be	 defined.	 Including	
metagenomics	 and	metabolomics	 data	 to	metataxonomics	 evidence	 accumulated	 to	
date	could	shed	some	light	to	the	field,	although	hypothesis-driven	research	should	be	
strongly	encouraged	to	minimize	the	risk	of	getting	“lost	in	transcription”.	
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6.	Expert	commentary	
Interpreting	 and	 comparing	 respiratory	 microbiota	 data	 across	 studies	 is	 a	 difficult	
task.	 The	main	 issue	when	 studying	 the	 respiratory	microbiota	 compared	 to	 the	 gut	
microbiota	is	the	invasiveness	of	lung	sampling.	Some	attempts	to	overcome	this	have	
been	suggested,	such	as	combining	nasopharyngeal	and	oropharyngeal	samples	based	
on	 the	 relationship	 between	 these	 sites	 and	 the	 lower	 respiratory	 tract	microbiota,	
and	 an	 interesting	 assessment	 of	 the	 lung	 microbiota	 through	 exhaled	 breath	
condensate	 fluid	 that	 showed	a	high	correlation	with	bronchoalveolar	 lavage	 fluid	 in	
intubated	patients79,	although	this	technique	does	not	seem	to	be	easily	applicable	to	
non-intubated	 patients.	 Besides	 the	 difference	 in	 samples,	 variability	 in	 sequencing	
techniques,	sequenced	regions,	library	preparation,	bioinformatics	tools	and	reference	
databases	 among	 others	 could	 yield	 different	 results.	 Kumar	 et	 al.,	 for	 example,	
reported	differences	 in	taxonomic	results	when	sequencing	different	variable	regions	
of	the	16SrRNA	gene	and	suggested	that	V1	to	V3,	and	V7	to	V9	showed	the	greatest	
utility	 in	classification.80	On	the	other	hand,	Kelly	et	al.	reported	similar	results	when	
comparing	 the	 performance	 of	 two	 sequencing	 platforms	 (Illumina	 MiSeq	 and	
Roche/454)	on	the	same	samples.51	To	avert	these	issues,	it	is	necessary	to	standardize	
existing	 techniques,	 to	 keep	 establishing	 associations	 between	 the	 microbiota	 from	
different	sampled	respiratory	sites,	and	ideally,	to	create	a	unique	genome	reference	
database.	 In	addition,	molecular	biology	tools	to	assess	viability	of	bacteria	 identified	
by	sequencing	methods	should	be	applied	when	possible.	This	would	help	reduce	the	
intricacy	of	microbiota	projects’	results	and	establishing	patterns,	a	key	step	to	move	
from	the	observational	nature	of	the	microbiota	studies	to	date	to	hypothesis	driven	
and	interventional	projects.		
	
Most	 of	 the	 studies	 assessing	 associations	 between	 the	 respiratory	 microbiota	 and	
disease	are	metataxonomic	studies	(i.e.,	based	on	16SrRNA	sequencing)	with	relatively	
small	 sample	 sizes.	 Even	with	 statistical	 corrective	measures	 to	 account	 for	multiple	
comparisons,	 spurious	 associations	 cannot	 completely	 be	 ruled	 out.	 Multiplicity	 of	
comparisons	 is	 an	 intrinsic	 issue	 in	 microbiota	 research	 because	 of	 the	 myriad	 of	
bacterial	 species	 co-existing	 in	 the	 human	body,	 and	 the	multiple	 characteristics	we	
use	to	describe	bacterial	communities,	i.e.,	evenness/dominance,	richness,	abundance	
and	presence	of	 specific	 taxa.	However,	 there	appears	 to	be	a	certain	consistency	 in	
microbiota	studies	where	diversity	is	usually	associated	with	health,	and	dominance	of	
a	 single	 species	 usually	 associated	 with	 disease.	 Importantly,	 these	 could	 just	 be	
proxies	 of	 respectively	 presence	 and	 absence	 of	 a	 particular	 bacterial	 consortium	
creating	a	specific	environment	with	protective	or	beneficial	effect.	This	hypothesis	is	
supported	 by	 some	 studies	 with	 animal	 models	 showing	 that	 resistance	 against	
Clostridium	difficile	colonization	was	not	conferred	by	any	single	bacterial	population,	
but	rather	by	combinations	of	different	commensals.81	
	
Moreover,	 the	dynamics	and	the	effect	over	 time	of	 the	respiratory	microbiota	have	
scarcely	been	studied	raising	reasonable	doubts	about	the	causal	relationship	between	
findings	in	microbiota	composition	and	disease.	Besides	the	cohort	study	conducted	by	
Teo	et	al.	and	described	in	the	“Asthma”	section,	another	cohort	study	led	by	Santee	
et	 al.	 showed	 that	 dominance	 of	 either	Moraxella,	 Streptococcus	 or	Haemophilus	 in	
the	 nasopharynx	 of	 children	 aged	 4	 to	 7	 years	 was	 associated	 with	 more	 frequent	
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upper	 respiratory	 tract	 infections	 including	 sinusitis	 over	 a	 1-year	 follow-up.82	 These	
findings	 should	 encourage	 researchers	 to	 conduct	 cohort	 studies	 in	 humans	 and	
interventional	 studies	 in	 animal	 models	 to	 validate	 the	 results	 from	 cross-sectional	
studies	as	a	necessary	step	towards	designing	preventive	measures	against	respiratory	
conditions	 based	 on	 the	 respiratory	 microbiota.	 Ideally,	 these	 potential	 novel	
measures	should	be	applicable	in	developing	countries,	the	world’s	region	that	suffers	
the	 highest	 burden	 of	 pediatric	 respiratory	 infections,	 and	 that	 is	 undergoing	 an	
epidemiological	transition	towards	a	double	burden	of	disease	with	an	important	role	
of	chronic	respiratory	conditions.	
7.	Five-years	view	
Currently,	 the	 dominance	 of	 host	 transcripts	 and	metabolites	 in	 respiratory	 samples	
obscures	 the	 interpretation	 of	 costly	 transcriptome	 and	 metabolome	 studies.	 With	
decreasing	 costs	 of	 culture-independent	 techniques,	 particularly	 whole	 genome	
sequencing,	 innovative	 solutions	 to	 overcome	 interpretation	 issues	 of	 results	 from	
omic	 platforms,	 and	 full	 integration	 with	 other	 disciplines	 (e.g.,	 immunology,	
bioinformatics,	microbiology,	epidemiology),	the	bacterial	microbiota	research	is	likely	
to	 become	 a	 true	 pan-microbiome	 field	 with	 a	 comprehensive	 understanding	 of	
bacterial,	viral,	fungal	and	host	interactions.	The	development	of	biobanks	are	a	good	
ally	for	this	endeavor,	insofar	it	will	enable	analyzing	large	numbers	of	stored	samples	
once	the	costs	of	omic	platforms	decrease	exponentially.	This	will	constitute	the	basics	
towards	 interventional	 research	 where	 probiotics,	 prebiotics	 and	 nutrition	 will	
probably	 be	 joined	 by	 phages	 and	 extremely	 narrow	 spectrum	 antibiotics	 as	 key	
interventions	to	build	a	healthy	respiratory	microbiota	to	be	used	as	a	preventive	and	
therapeutic	 measure.	 Taking	 into	 account	 environmental	 effects,	 population	 and	
individual	 diversity,	 cross-talk	 between	 microbial	 communities	 from	 different	 body	
sites,	 and	 the	 effects	 of	 the	 microbiota	 on	 different	 diseases	 and	 conditions,	 the	
microbiome	research	could	become	one	of	the	pillars	of	personalized	medicine.		
	
Key	issues	
• The	 respiratory	 tract	 is	 a	 complex	 ecosystem	 with	 distinct	 bacterial	
communities	present	in	every	niche,	including	the	lungs.	
• The	 respiratory	 microbiota	 seems	 to	 have	 an	 effect	 on	 lower	 respiratory	
infections	and	infectious-related	conditions,	where	host-microbe	and	microbe-
microbe	interactions	are	not	yet	completely	understood.	
• Although	 microbiota	 diversity	 is	 usually	 associated	 with	 health,	 it	 is	 unclear	
whether	 diversity	 may	 mask	 the	 presence	 of	 protective	 bacterial	 consortia.	
Moreover,	 differences	 in	 children	 and	adults	might	be	evidence	of	 important	
interactions	associated	with	immune	system	development.	
• Prospective	studies	with	serial	samples	to	describe	the	respiratory	microbiome	
acquisition	 and	 dynamics,	 and	 to	 determine	 long-term	 effects	 on	 respiratory	
conditions	are	needed	to	exploit	 the	 translational	potential	of	 the	 respiratory	
microbiome.	
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Box	1.	Search	strategy	and	selection	criteria	
	
	
	
Table	1.	Terminology	frequently	used	in	microbiome	research	
	
Terminology	 	
Microbiota	 Collection	of	microorganisms	present	in	a	particular	site	
Microbiome	 Collection	of	microorganisms	in	a	particular	site,	their	genes,	
and	the	surrounding	environmental	conditions	
Mycobiome	 The	entire	genomic	content	of	fungi	in	a	particular	site	
Virome	 The	entire	genomic	content	of	viruses	in	a	particular	site	
Metataxonomics	 High-throughput	process	to	characterize	the	microbiota	and	to	
establish	taxonomic	associations,	usually	by	16S	rRNA	
sequencing	
Metagenomics	 High-throughput	process	to	characterize	the	pool	of	genes	from	
members	of	a	microbiota,	usually	by	shotgun	sequencing	
Metatranscriptomics	 High-throughput	process	to	identify	and	quantify	microbial	
genes	that	are	expressed	by	the	microbiota	
Metabolomics	 Study	of	products	of	cellular	metabolism	in	a	defined	
environment,	including	host’s	and	microbe’s	metabolites	
Next-generation	
sequencing	
In	contrast	with	Sanger	sequencing,	NGS	is	based	on	parallel	
sequencing	of	vast	numbers	of	short	reads	
Whole-genome	
Shotgun	sequencing	
Method	to	characterize	whole	genomes	by	sequencing	a	large	
number	of	random	small	DNA	fragments	in	parallel	and	
assembling	them	into	larger	contigs	
16S	rRNA	gene	
sequencing	
Method	to	characterize	bacterial	populations	by	sequencing	
variable	regions	of	the	highly	conserved	bacterial	16S	rRNA	
gene	
Operational	
Taxonomic	Unit	
Clusters	of	similar	sequence	variants	of	the	16S	rRNA	gene	used	
as	a	surrogate	for	taxa	in	metataxonomics	studies.	97%	
We	searched	PubMed	(accessed	on	February	18th	2017)	and	the	reference	 lists	of	
selected	 papers	 to	 identify	 studies	 assessing	 the	 association	 between	 respiratory	
microbiota	 and	 lower	 respiratory	 infections,	 limited	 to	 humans,	 and	 with	 no	
language	 restriction.	We	 limited	 the	 search	 to	 studies	 using	 culture-independent	
techniques	 to	 identify	 and	 classify	 bacterial	 populations	 in	 order	 to	 increase	
comparability.	 We	 used	 a	 combination	 of	 search	 terms	 as	 both	 free	 and	 MeSH	
terms	when	applicable,	to	optimize	sensitivity:	((microbiome)	OR	(microbiota))	AND	
((airway*)	 OR	 (respiratory	 tract)	 OR	 (nose)	 OR	 (nasal)	 OR	 (mouth)	 OR	 (oral)	 OR	
(pharyn*)	 OR	 (nasopharyn*)	 OR	 (oropharyn*)	 OR	 (lung)	 OR	 (pulmonar*))	 AND	
((pneumonia)	OR	(bronchiolitis)	OR	(LRTI)	OR	(lower	respiratory	tract	infection)	OR	
(ARTI)	 OR	 (acute	 respiratory	 tract	 infection)	 OR	 (ARI)	 OR	 (acute	 respiratory	
infection)).	A	total	of	125	articles	were	obtained	after	excluding	animal	studies.	We	
screened	titles	and	abstracts,	and	we	retained	original	papers	within	the	scope	of	
the	review.		
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(OTU)	 similarity	is	commonly	used	as	cut-off	for	species	surrogate	
Abundance	 Total	number	of	bacterial	individuals	in	a	sample	
Richness	 Number	of	different	species/OTUs	present	in	a	sample	
Evenness	 Measure	of	similarity	in	relative	abundance	/	frequency	
distribution	of	OTUs	within	a	community.	Dominance	of	one	
taxa	implies	decreased	evenness	
Alpha	Diversity	 Measure	of	diversity	within	a	sample,	taking	into	account	
richness	and/or	evenness.	Commonly	used	metrics	of	α-
diversity	include	Chao1,	Shannon	and	Simpson	indexes	
Chao	1	Index	 Measure	of	observed	and	unobserved	richness	
Shannon	Index	 Measure	of	diversity	combining	richness	and	evenness.	Higher	
values	indicate	higher	diversity	
Simpson	Index	 Measure	of	dominance	(complimentary	measure	of	evenness).	
Higher	values	indicate	lower	evenness	
Beta	Diversity	 Measure	of	diversity	between	samples.	High	β-diversity	implies	
large	dissimilarities	between	samples	
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Table	2.	Overview	of	study	characteristics	included	in	the	systematic	review	(Adults)	
	
Author,	year	 Study	design	 Sample	size	 Baseline	
condition	
Outcome	of	
interest	
Respiratory	
sample	
NGS		
(variable	region)	
Reference	
de	Steenhuijsen,	2016	 Case-control	 127	cases	
278	controls	
None	 Pneumonia	 OP	swab	 16S	rRNA	
(V5-V7)	
46	
Kawanani,	2016	 Cohort	 42	 None	 MRSA	
pneumonia	
BAL	 16S	rRNA	
	
50	
Kelly,	2016	 Cohort	 15	 Intubated	
patients	
VAP	 OP	swab	
BAL	
16S	rRNA	
(V1-V2)	
51	
Lu,	2015	 Case-control	 30	cases	
60	controls	
Cirrhosis	 Pneumonia	 OP	swab	 16S	rRNA	
(V3)	
52	
Shankar,	2016	 Cross-sectional	 16	 Lung	transplant	 Pneumonia	 BAL	 16S	rRNA	
(V4)	
55	
Toma,	2014	 Cross-sectional	 44	 Intubated	
patients	
VAP	 ET	aspirate	 16S	rRNA	
V1-V9	
56	
Zakhakina,	2017	 Cohort	 35	 Intubated	
patients	
VAP	 ET	aspirate	 16S	rRNA	
	
58	
Willner,	2013	 Cohort	 57	 Lung	transplant	 BOS	 BAL	 16S	rRNA	
(V7-V8)	
57	
Dickson,	2014	 Case-control	 33	cases	
26	controls	
Lung	transplant	 BOS	 BAL	 16S	rRNA	
(V3-V5)	
47	
Flight,	2015	 Cross-sectional	 59	 Cystic	fibrosis	 Lung	function	 Sputum	 16S	rRNA	
	
48	
Garzoni,	2014	 Case-control	 18	cases	
15	controls	
	
Interstitial	lung	
disease	
NA	 OP	swab	
BAL	
16S	rRNA	
(V3-V5)	
49	
Molyneaux,	2014	 Cohort	 65	 Idiopathic	
pulmonary	
fibrosis	
Lung	function	 BAL	 16S	rRNA	
(V3-V5)	
53	
Rogers,	2013	 Cross-sectional	 41	 Non-CF	
bronchiectasis	
Lung	function	 BAL	
Sputum	
16S	rRNA	
	
54	
OP:	oropharyngeal;	MRSA:	methicillin	resistant	S.	aureus;	BAL:	bronchoalveolar	lavage;	VAP:	ventilator-associated	pneumonia;	ET:	endotracheal;	BOS:	bronchiolitis	obliterans	syndrome	
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Table	3.	Overview	of	study	characteristics	included	in	the	systematic	review	(Children)	
	
Author,	year	 Study	design	 Sample	size	 Baseline	condition	 Outcome	of	
interest	
Respiratory	
sample	
NGS	(variable	
region)	
Reference	
Lu,	2014	 Cross-sectional	 25	 Intubated	
newborns	
VAP	 ET	aspirate	 16S	rRNA	
(V3)	
63	
Pettigrew,	2016	 Cohort	 383	 Pneumonia	 Severity	 Sputum	
NP	swab	
OP	swab	
16S	rRNA	
(V4)	
66	
Sakwinska,	2014	 Case-control	 50	cases	
50	controls	
None	 Pneumonia	 NP	swab	 16S	rRNA	
(V1-V2)	
67	
Wang,	2016	 Case-control	 21	cases	
11	controls	
None	 Pneumonia	 BAL	 16S	rRNA	
(V3-V4)	
68	
Castro-Callar,	
2015	
Case-control	 8	cases	
6	controls	
None	 Asthma	 Nasal	brush	 Whole	genome	
shotgun	
59	
Hasegawa,	2016	 Case-control	 40	cases	
110	controls	
None	 Bronchiolitis	 Nasal	swab	 16S	rRNA	
(V4)	
60	
Hasegawa,	2016	 Cross-sectional	 1005	 Bronchiolitis	 ICU	admission	 NP	aspirate	 16S	rRNA	
(V4)	
61	
Hyde,	2014	 Cross-sectional	 100	 Bronchiolitis	 NA	 NP	aspirate	 16S	rRNA	
(V3-V5)	
62	
Mansbach,	2016	 Cross-sectional	 740	 Bronchiolitis	 NA	 NP	aspirate	 16S	rRNA	
(V4)	
64	
Teo,	2015	 Cohort	 234	 High	risk	of	atopy	 Asthma	
LRI	
NP	aspirate	 16S	rRNA	
(V4)	
19	
Zhou,	2016	 Cohort	 39	 Bronchiolitis	 Recurrent	
wheezing	
Nasal	lavage	 16S	rRNA	
(V1-V3)	
69	
VAP:	ventilator-associated	pneumonia;	ET:	endotracheal;	NP:	nasopharyngeal;	OP:	oropharyngeal;	BAL:	bronchoalveolar	lavage;	ICU:	intensive	care	unit;	LRI:	lower	respiratory	infection	
	
